|
G
|
Acaca
|
acetyl-CoA carboxylase alpha
|
decreases expression
|
EXP
|
Carnitine results in decreased expression of ACACA protein
|
CTD |
PMID:25669660 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G
|
Acacb
|
acetyl-CoA carboxylase beta
|
decreases expression
|
EXP
|
Carnitine results in decreased expression of ACACB protein
|
CTD |
PMID:25669660 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
increases expression
|
EXP
|
Carnitine results in increased expression of ADIPOQ protein
|
CTD |
PMID:30256492 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions increases phosphorylation
|
EXP
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:29186614 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G
|
App
|
amyloid beta precursor protein
|
multiple interactions
|
ISO
|
Carnitine promotes the reaction [Paraquat deficiency inhibits the reaction [Paraquat promotes the reaction [APP protein binds to APP protein]]]
|
CTD |
PMID:33290254 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
decreases expression multiple interactions
|
EXP
|
Carnitine results in decreased expression of BAX protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein]; Carnitine inhibits the reaction [Atrazine results in increased expression of BAX mRNA]; Carnitine inhibits the reaction [Methotrexate results in increased expression of BAX protein]
|
CTD |
PMID:29186614 PMID:36282381 PMID:37312617 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G
|
Bbox1
|
gamma-butyrobetaine hydroxylase 1
|
multiple interactions increases chemical synthesis
|
ISO
|
Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]; Ketoglutaric Acids inhibits the reaction [Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]
|
CTD |
PMID:21439360 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions increases phosphorylation
|
EXP
|
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; Carnitine inhibits the reaction [Atrazine results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]
|
CTD |
PMID:23213347 PMID:29186614 PMID:36282381 PMID:37312617 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Gentamicins results in decreased expression of BCL2L1 protein]
|
CTD |
PMID:19491382 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases expression
|
EXP ISO
|
Carnitine inhibits the reaction [Atrazine results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of CASP3 mRNA]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of CASP3 protein] Carnitine results in increased expression of CASP3 protein Carnitine inhibits the reaction [quinone results in increased activity of CASP3 protein]
|
CTD |
PMID:19491382 PMID:23213347 PMID:25669660 PMID:26562095 PMID:32478940 PMID:36282381 PMID:37312617 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions
|
ISO
|
Carnitine inhibits the reaction [quinone results in increased activity of CASP8 protein]
|
CTD |
PMID:32478940 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions
|
EXP ISO
|
Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA] Carnitine inhibits the reaction [quinone results in increased activity of CASP9 protein]
|
CTD |
PMID:23213347 PMID:32478940 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA]
|
CTD |
PMID:16889571 PMID:19294768 PMID:23213347 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G
|
Ccn2
|
cellular communication network factor 2
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Sunitinib results in increased expression of CCN2 mRNA]
|
CTD |
PMID:26581635 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G
|
Cdh1
|
cadherin 1
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CDH1 protein]
|
CTD |
PMID:28973641 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of COL1A1 mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of COL1A1 mRNA]
|
CTD |
PMID:26581635 PMID:28973641 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G
|
Col2a1
|
collagen type II alpha 1 chain
|
multiple interactions
|
EXP
|
[COL2A1 protein co-treated with Freund's Adjuvant] affects the abundance of Carnitine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]
|
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G
|
Cpt1a
|
carnitine palmitoyltransferase 1A
|
multiple interactions
|
EXP ISO
|
valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Carnitine] [Doxorubicin co-treated with Carnitine] results in increased expression of CPT1A mRNA; [Genistein co-treated with Carnitine] results in increased expression of CPT1A protein; Carnitine inhibits the reaction [quinone results in decreased expression of CPT1A protein]
|
CTD |
PMID:16283381 PMID:16362726 PMID:19854160 PMID:32478940 |
|
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G
|
Cpt2
|
carnitine palmitoyltransferase 2
|
multiple interactions increases expression
|
ISO EXP
|
Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate] Carnitine results in increased expression of CPT2 protein
|
CTD |
PMID:21816645 PMID:25669660 |
|
NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:122,664,677...122,682,095
|
|
G
|
Cybb
|
cytochrome b-245 beta chain
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB protein]
|
CTD |
PMID:26581635 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G
|
Cyp17a1
|
cytochrome P450, family 17, subfamily a, polypeptide 1
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Atrazine results in decreased expression of CYP17A1 mRNA]
|
CTD |
PMID:29710542 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions
|
EXP
|
Carnitine promotes the reaction [Ethanol results in increased expression of CYP2E1 protein]
|
CTD |
PMID:8130774 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G
|
Fabp3
|
fatty acid binding protein 3
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Doxorubicin results in decreased expression of FABP3 mRNA]
|
CTD |
PMID:20470772 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G
|
Fabp9
|
fatty acid binding protein 9
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein]
|
CTD |
PMID:33965443 |
|
NCBI chr 2:91,591,842...91,595,873
Ensembl chr 2:91,592,298...91,595,873
|
|
G
|
Fasn
|
fatty acid synthase
|
decreases expression
|
EXP
|
Carnitine results in decreased expression of FASN protein
|
CTD |
PMID:25669660 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,072,091...106,090,261
|
|
G
|
Fshb
|
follicle stimulating hormone subunit beta
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in decreased expression of FSHB protein]
|
CTD |
PMID:33965443 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G
|
Gdf9
|
growth differentiation factor 9
|
multiple interactions increases expression
|
ISO
|
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GDF9 mRNA] Carnitine results in increased expression of GDF9 mRNA
|
CTD |
PMID:37863343 |
|
NCBI chr10:37,589,200...37,599,970
Ensembl chr10:37,595,679...37,599,672
|
|
G
|
Gfap
|
glial fibrillary acidic protein
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Atrazine results in increased expression of GFAP protein]
|
CTD |
PMID:36282381 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G
|
Gja1
|
gap junction protein, alpha 1
|
multiple interactions increases expression
|
ISO
|
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA1 mRNA] Carnitine results in increased expression of GJA1 mRNA
|
CTD |
PMID:37863343 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:35,755,991...35,768,582
|
|
G
|
Gja4
|
gap junction protein, alpha 4
|
increases expression multiple interactions
|
ISO
|
Carnitine results in increased expression of GJA4 mRNA Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA4 mRNA]
|
CTD |
PMID:37863343 |
|
NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925
|
|
G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Atrazine results in increased activity of GPT protein]
|
CTD |
PMID:36282381 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G
|
Gpx1
|
glutathione peroxidase 1
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Ifosfamide results in decreased expression of GPX1 mRNA]
|
CTD |
PMID:23213347 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G
|
Hadha
|
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha
|
multiple interactions
|
ISO
|
Carnitine inhibits the reaction [quinone results in decreased expression of HADHA protein]
|
CTD |
PMID:32478940 |
|
NCBI chr 6:31,907,801...31,947,434
Ensembl chr 6:26,187,956...26,227,869
|
|
G
|
Has2
|
hyaluronan synthase 2
|
multiple interactions increases expression
|
ISO
|
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of HAS2 mRNA] Carnitine results in increased expression of HAS2 mRNA
|
CTD |
PMID:37863343 |
|
NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Methotrexate results in decreased expression of HMOX1 protein]
|
CTD |
PMID:37312617 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G
|
Hrk
|
harakiri, BCL2 interacting protein
|
multiple interactions
|
ISO
|
Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK protein]
|
CTD |
PMID:16239342 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G
|
Hspa2
|
heat shock protein family A (Hsp70) member 2
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Cadmium Chloride results in increased expression of HSPA2 protein]
|
CTD |
PMID:22359436 |
|
NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287
|
|
G
|
Idh2
|
isocitrate dehydrogenase (NADP(+)) 2
|
multiple interactions increases abundance
|
ISO
|
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Carnitine]
|
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]; Carnitine inhibits the reaction [Sunitinib results in decreased expression of IL10 mRNA]
|
CTD |
PMID:26581635 PMID:33965443 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G
|
Il18
|
interleukin 18
|
increases expression
|
EXP
|
Carnitine results in increased expression of IL18 protein
|
CTD |
PMID:25669660 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases expression
|
EXP
|
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of IL1B mRNA]]; Carnitine inhibits the reaction [sunitinib results in increased expression of IL1B mRNA] Carnitine results in increased expression of IL1B protein
|
CTD |
PMID:25669660 PMID:26562095 PMID:26581635 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Methotrexate results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Sunitinib results in increased expression of IL6 mRNA]
|
CTD |
PMID:26581635 PMID:33965443 PMID:37312617 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G
|
Ins1
|
insulin 1
|
decreases uptake multiple interactions
|
ISO EXP
|
INS1 protein results in decreased uptake of Carnitine Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased secretion of INS1 protein]
|
CTD |
PMID:28298333 PMID:30256492 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G
|
Ldha
|
lactate dehydrogenase A
|
multiple interactions
|
ISO
|
Carnitine inhibits the reaction [Doxorubicin results in increased activity of LDHA protein]
|
CTD |
PMID:37453608 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G
|
Lepr
|
leptin receptor
|
affects abundance
|
ISO
|
LEPR affects the abundance of Carnitine
|
CTD |
PMID:20567778 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G
|
Lhb
|
luteinizing hormone subunit beta
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in decreased expression of LHB protein]
|
CTD |
PMID:33965443 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [sunitinib results in decreased expression of MMP9 mRNA]
|
CTD |
PMID:26581635 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions increases activity
|
EXP
|
[Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased activity of MPO protein]
|
CTD |
PMID:18597074 PMID:18852009 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G
|
Mt-co1
|
mitochondrially encoded cytochrome c oxidase I
|
multiple interactions
|
ISO
|
Carnitine inhibits the reaction [nickel chloride results in decreased expression of COX1 mRNA]
|
CTD |
PMID:21419151 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G
|
Mt-nd6
|
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6
|
multiple interactions
|
ISO
|
Carnitine inhibits the reaction [nickel chloride results in decreased expression of ND6 mRNA]
|
CTD |
PMID:21419151 |
|
NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061 NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061
|
|
G
|
Mttp
|
microsomal triglyceride transfer protein
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Stavudine results in decreased expression of MTTP mRNA]
|
CTD |
PMID:18299183 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein]
|
CTD |
PMID:37312617 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
increases expression
|
EXP
|
Carnitine results in increased expression of NLRP3 protein
|
CTD |
PMID:25669660 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA]
|
CTD |
PMID:23213347 PMID:33965443 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G
|
Nos3
|
nitric oxide synthase 3
|
increases expression
|
EXP
|
Carnitine results in increased expression of NOS3
|
CTD |
PMID:20123095 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G
|
Ocln
|
occludin
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in decreased expression of OCLN protein]
|
CTD |
PMID:33965443 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions increases expression increases activity
|
EXP
|
[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]; PPARA protein promotes the reaction [Carnitine results in decreased susceptibility to Gentamicins] Carnitine results in increased expression of PPARA protein Carnitine results in increased activity of PPARA protein
|
CTD |
PMID:19491382 PMID:19735737 PMID:25669660 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
increases expression multiple interactions
|
EXP
|
Carnitine results in increased expression of PPARG protein Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of PPARG protein]
|
CTD |
PMID:30256492 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Methotrexate results in decreased expression of PPARGC1A protein]
|
CTD |
PMID:37312617 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G
|
Ptgis
|
prostaglandin I2 synthase
|
increases expression increases response to substance multiple interactions
|
EXP
|
Carnitine results in increased expression of PTGIS mRNA PTGIS protein results in increased susceptibility to Carnitine [Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha
|
CTD |
PMID:19491382 |
|
NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451
|
|
G
|
Pycard
|
PYD and CARD domain containing
|
increases expression
|
EXP
|
Carnitine results in increased expression of PYCARD protein
|
CTD |
PMID:25669660 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in increased expression of RELA protein]
|
CTD |
PMID:33965443 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G
|
Scd
|
stearoyl-CoA desaturase
|
decreases expression
|
EXP
|
Carnitine results in decreased expression of SCD protein
|
CTD |
PMID:25669660 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:243,269,747...243,282,562
|
|
G
|
Sirt1
|
sirtuin 1
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Methotrexate results in decreased expression of SIRT1 protein]
|
CTD |
PMID:37312617 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G
|
Sirt3
|
sirtuin 3
|
multiple interactions
|
ISO
|
Carnitine inhibits the reaction [Cyclophosphamide results in increased expression of SIRT3 mRNA]
|
CTD |
PMID:37863343 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:195,942,073...195,964,808
|
|
G
|
Slc22a1
|
solute carrier family 22 member 1
|
decreases expression
|
EXP
|
Carnitine results in decreased expression of SLC22A1 protein
|
CTD |
PMID:25669660 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G
|
Slc22a2
|
solute carrier family 22 member 2
|
decreases expression
|
EXP
|
Carnitine results in decreased expression of SLC22A2 protein
|
CTD |
PMID:25669660 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G
|
Slc22a21
|
solute carrier family 22 (organic cation transporter), member 21
|
multiple interactions increases uptake
|
EXP
|
[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]
|
CTD |
PMID:19735737 |
|
NCBI chr10:38,104,114...38,133,106
Ensembl chr10:38,104,122...38,130,671
|
|
G
|
Slc22a4
|
solute carrier family 22 member 4
|
increases uptake decreases expression
|
ISO EXP
|
SLC22A4 protein results in increased uptake of Carnitine Carnitine results in decreased expression of SLC22A4 protein
|
CTD |
PMID:21256917 PMID:25669660 PMID:33007874 |
|
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
|
|
G
|
Slc22a5
|
solute carrier family 22 member 5
|
multiple interactions affects expression decreases expression increases transport increases uptake increases expression affects uptake affects binding
|
ISO EXP
|
[Doxorubicin co-treated with Carnitine] results in increased expression of SLC22A5 mRNA; Amiodarone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of Doxorubicin]; Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; Choline inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Clozapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ipratropium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Propranolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Spironolactone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; talinolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; ziprasidone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine affects the expression of SLC22A5 protein Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of and results in increased localization of Doxorubicin] Carnitine results in decreased expression of SLC22A5 mRNA; Carnitine results in decreased expression of SLC22A5 protein 1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [SLC22A5 protein results in increased uptake of Tetraethylammonium]; Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine deficiency results in increased expression of SLC22A5 mRNA SLC22A5 protein results in increased uptake of Carnitine; SLC22A5 protein results in increased uptake of Carnitine analog SLC22A5 protein affects the uptake of Carnitine Carnitine binds to SLC22A5 protein
|
CTD |
PMID:12644265 PMID:15486076 PMID:16283381 PMID:16928358 PMID:18762717 PMID:18981167 PMID:19041296 PMID:19539806 PMID:19735737 PMID:20303936 PMID:20470772 PMID:21256917 PMID:21641380 PMID:22701146 PMID:25669660 PMID:30465787 PMID:31437515 PMID:33007874 PMID:37453608 More...
|
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G
|
Slc22a8
|
solute carrier family 22 member 8
|
increases transport
|
ISO
|
SLC22A8 protein results in increased transport of Carnitine
|
CTD |
PMID:15100168 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G
|
Slc25a20
|
solute carrier family 25 member 20
|
multiple interactions increases transport
|
EXP
|
Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Carnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]
|
CTD |
PMID:18452908 PMID:23402788 |
|
NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
|
|
G
|
Slc2a4
|
solute carrier family 2 member 4
|
increases expression multiple interactions
|
EXP
|
Carnitine results in increased expression of SLC2A4 protein Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SLC2A4 protein]
|
CTD |
PMID:30256492 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G
|
Snai1
|
snail family transcriptional repressor 1
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of SNAI1 protein]
|
CTD |
PMID:28973641 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G
|
Srebf1
|
sterol regulatory element binding transcription factor 1
|
multiple interactions decreases expression
|
EXP
|
Carnitine inhibits the reaction [Stavudine results in increased expression of SREBF1 mRNA] Carnitine results in decreased expression of SREBF1 protein
|
CTD |
PMID:18299183 PMID:25669660 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G
|
Star
|
steroidogenic acute regulatory protein
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein]
|
CTD |
PMID:33965443 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TGFB1 mRNA]]; Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TGFB1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of TGFB1 mRNA]
|
CTD |
PMID:26562095 PMID:26581635 PMID:28973641 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [sunitinib results in increased expression of TIMP1 mRNA]
|
CTD |
PMID:26581635 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G
|
Tjp1
|
tight junction protein 1
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein]
|
CTD |
PMID:28973641 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression multiple interactions decreases expression
|
EXP
|
Carnitine deficiency results in increased expression of TNF mRNA [Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased expression of TNF mRNA]; Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF mRNA]]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF protein]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of TNF protein] Carnitine results in decreased expression of TNF protein
|
CTD |
PMID:18597074 PMID:18629605 PMID:18852009 PMID:26562095 PMID:33965443 PMID:37312617 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G
|
Vim
|
vimentin
|
multiple interactions
|
EXP
|
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of VIM protein]
|
CTD |
PMID:28973641 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187
|
|
|
G
|
Bbox1
|
gamma-butyrobetaine hydroxylase 1
|
multiple interactions
|
ISO
|
[BBOX1 protein co-treated with Ketoglutaric Acids] results in increased metabolism of gamma-butyrobetaine
|
CTD |
PMID:21439360 |
|
NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458
|
|
G
|
Idh2
|
isocitrate dehydrogenase (NADP(+)) 2
|
multiple interactions increases abundance
|
ISO
|
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of gamma-butyrobetaine]
|
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G
|
Slc22a5
|
solute carrier family 22 member 5
|
affects binding increases uptake multiple interactions increases transport
|
ISO EXP
|
pivaloylcarnitine binds to SLC22A5 protein SLC22A5 protein results in increased uptake of pivaloylcarnitine Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]
|
CTD |
PMID:18762717 PMID:19539806 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
|
G
|
Acacb
|
acetyl-CoA carboxylase beta
|
decreases expression
|
EXP
|
L-carnitine decreases expression of Acacb mRNA and protein in rat heart
|
RGD |
PMID:30644033 |
RGD:329955369 |
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G
|
Cpt1a
|
carnitine palmitoyltransferase 1A
|
increases expression multiple interactions
|
EXP
|
L-carnitine increases expression of Cpt1a mRNA and protein in rat heart L-carnitine inhibits the reaction [sunitinib decreases expression of Cpt1a mRNA and protein in rat heart]
|
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055
|
|
G
|
Mlycd
|
malonyl-CoA decarboxylase
|
increases expression multiple interactions
|
EXP
|
L-carnitine increases expression of Mlycd protein in rat heart L-carnitine inhibits the reaction [sunitinib increases expression of Mlycd protein in rat heart]
|
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793
|
|
G
|
Prkaa2
|
protein kinase AMP-activated catalytic subunit alpha 2
|
increases expression multiple interactions
|
EXP
|
L-carnitine increases expression of Ampka2 protein in rat serum and heart L-carnitine inhibits the reaction [sunitinib decreases expression of Ampka2 protein in rat serum and heart]
|
RGD |
PMID:30644033 PMID:30644033 |
RGD:329955369, RGD:329955369 |
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
|
G
|
Ache
|
acetylcholinesterase
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [Dexamethasone results in decreased activity of ACHE protein]; Acetylcarnitine inhibits the reaction [Dexamethasone results in increased activity of ACHE protein]
|
CTD |
PMID:21986892 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G
|
Apex1
|
apurinic/apyrimidinic endodeoxyribonuclease 1
|
increases expression
|
EXP
|
Acetylcarnitine results in increased expression of APEX1 mRNA
|
CTD |
PMID:14654561 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G
|
Atp6v1f
|
ATPase H+ transporting V1 subunit F
|
increases expression
|
EXP
|
Acetylcarnitine results in increased expression of ATP6V1F mRNA
|
CTD |
PMID:14654561 |
|
NCBI chr 4:58,067,666...58,070,628
|
|
G
|
C1qa
|
complement C1q A chain
|
decreases expression
|
ISO
|
Acetylcarnitine results in decreased expression of C1QA mRNA
|
CTD |
PMID:19555370 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G
|
C4b
|
complement C4B
|
decreases expression
|
ISO
|
Acetylcarnitine results in decreased expression of C4B mRNA
|
CTD |
PMID:19555370 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of CASP3 mRNA]
|
CTD |
PMID:20067779 PMID:29278859 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP9 protein]
|
CTD |
PMID:29278859 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G
|
Cat
|
catalase
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of CAT mRNA]
|
CTD |
PMID:20067779 PMID:26349760 PMID:29278859 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G
|
Col2a1
|
collagen type II alpha 1 chain
|
multiple interactions
|
EXP
|
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Acetylcarnitine
|
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G
|
Cs
|
citrate synthase
|
decreases activity
|
EXP
|
Acetylcarnitine results in decreased activity of CS protein
|
CTD |
PMID:9821151 |
|
NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:758,345...791,421
|
|
G
|
Ctss
|
cathepsin S
|
decreases expression
|
ISO
|
Acetylcarnitine results in decreased expression of CTSS mRNA
|
CTD |
PMID:19555370 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G
|
Cxcl14
|
C-X-C motif chemokine ligand 14
|
decreases expression
|
ISO
|
Acetylcarnitine results in decreased expression of CXCL14 mRNA
|
CTD |
PMID:19555370 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G
|
Egr1
|
early growth response 1
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of EGR1 mRNA]
|
CTD |
PMID:20067779 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G
|
Gfap
|
glial fibrillary acidic protein
|
decreases expression
|
ISO
|
Acetylcarnitine results in decreased expression of GFAP mRNA
|
CTD |
PMID:19555370 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G
|
Gsr
|
glutathione-disulfide reductase
|
multiple interactions
|
ISO
|
Acetylcarnitine inhibits the reaction [Acetaminophen results in decreased expression of GSR protein]
|
CTD |
PMID:26265018 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G
|
Gstp1
|
glutathione S-transferase pi 1
|
multiple interactions
|
EXP
|
Acetylcarnitine affects the reaction [Dexamethasone results in decreased expression of GSTP1 mRNA]
|
CTD |
PMID:21986892 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226
|
|
G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions
|
EXP
|
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX1 mRNA]
|
CTD |
PMID:21986892 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G
|
Hmox2
|
heme oxygenase 2
|
multiple interactions
|
EXP
|
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of HMOX2 mRNA]
|
CTD |
PMID:21986892 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G
|
Hspb1
|
heat shock protein family B (small) member 1
|
decreases expression
|
EXP
|
Acetylcarnitine results in decreased expression of HSPB1 mRNA
|
CTD |
PMID:14654561 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G
|
Idh2
|
isocitrate dehydrogenase (NADP(+)) 2
|
increases abundance multiple interactions
|
ISO
|
IDH2 protein mutant form results in increased abundance of Acetylcarnitine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Acetylcarnitine]
|
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]
|
CTD |
PMID:29278859 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of IL6 protein]
|
CTD |
PMID:29278859 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G
|
Mgst1
|
microsomal glutathione S-transferase 1
|
increases expression
|
EXP
|
Acetylcarnitine results in increased expression of MGST1 mRNA
|
CTD |
PMID:14654561 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G
|
Mt-co1
|
mitochondrially encoded cytochrome c oxidase I
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of COX1 mRNA]
|
CTD |
PMID:20067779 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G
|
Ngf
|
nerve growth factor
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [Cisplatin results in decreased expression of NGF protein]
|
CTD |
PMID:14654561 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G
|
Nos1
|
nitric oxide synthase 1
|
multiple interactions
|
EXP
|
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS1 mRNA]
|
CTD |
PMID:21986892 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
EXP
|
Acetylcarnitine affects the reaction [Dexamethasone results in increased expression of NOS2 mRNA]
|
CTD |
PMID:21986892 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G
|
Pah
|
phenylalanine hydroxylase
|
decreases expression
|
ISO
|
Acetylcarnitine results in decreased expression of PAH mRNA
|
CTD |
PMID:19555370 |
|
NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130
|
|
G
|
Pink1
|
PTEN induced kinase 1
|
multiple interactions
|
ISO
|
Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PINK1]
|
CTD |
PMID:25464205 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
increases expression multiple interactions
|
ISO
|
Acetylcarnitine results in increased expression of PPARGC1A protein [Acetylcarnitine co-treated with Thioctic Acid] results in increased expression of PPARGC1A protein
|
CTD |
PMID:20414966 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G
|
Prkn
|
parkin RBR E3 ubiquitin protein ligase
|
multiple interactions
|
ISO
|
Acetylcarnitine inhibits the reaction [Cadmium results in increased expression of PRKN]
|
CTD |
PMID:25464205 |
|
NCBI chr 1:51,236,410...52,430,242
Ensembl chr 1:48,690,556...49,882,555
|
|
G
|
Psmb6
|
proteasome 20S subunit beta 6
|
increases expression
|
EXP
|
Acetylcarnitine results in increased expression of PSMB6 mRNA
|
CTD |
PMID:14654561 |
|
NCBI chr10:55,239,256...55,241,586
Ensembl chr10:55,239,241...55,241,586
|
|
G
|
Ptma
|
prothymosin alpha
|
increases expression
|
EXP
|
Acetylcarnitine results in increased expression of PTMA mRNA
|
CTD |
PMID:14654561 |
|
NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased expression of RELA protein]
|
CTD |
PMID:29278859 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G
|
Rps17
|
ribosomal protein S17
|
increases expression
|
EXP
|
Acetylcarnitine results in increased expression of RPS17 mRNA
|
CTD |
PMID:14654561 |
|
NCBI chr 1:135,295,920...135,298,506
Ensembl chr 1:135,295,919...135,298,535 Ensembl chr 8:135,295,919...135,298,535
|
|
G
|
Skap2
|
src kinase associated phosphoprotein 2
|
decreases expression
|
ISO
|
Acetylcarnitine results in decreased expression of SKAP2 mRNA
|
CTD |
PMID:19555370 |
|
NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891
|
|
G
|
Slc25a20
|
solute carrier family 25 member 20
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]
|
CTD |
PMID:23402788 |
|
NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
|
|
G
|
Snca
|
synuclein alpha
|
multiple interactions
|
ISO
|
[Acetylcarnitine co-treated with Thioctic Acid] inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Acetylcarnitine inhibits the reaction [Rotenone results in increased expression of SNCA protein]
|
CTD |
PMID:20414966 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G
|
Tnni3
|
troponin I3, cardiac type
|
multiple interactions
|
EXP
|
Acetylcarnitine inhibits the reaction [Cisplatin results in increased expression of TNNI3 protein]
|
CTD |
PMID:21034734 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
|
G
|
Idh2
|
isocitrate dehydrogenase (NADP(+)) 2
|
multiple interactions increases abundance
|
ISO
|
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of butyrylcarnitine]
|
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G
|
Crot
|
carnitine O-octanoyltransferase
|
increases chemical synthesis
|
ISO
|
CROT protein results in increased chemical synthesis of octanoylcarnitine
|
CTD |
PMID:6838215 |
|
NCBI chr 4:26,031,729...26,088,057
Ensembl chr 4:25,080,587...25,133,109
|
|
|
G
|
Col2a1
|
collagen type II alpha 1 chain
|
multiple interactions
|
EXP
|
[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Palmitoylcarnitine
|
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G
|
Gls
|
glutaminase
|
increases chemical synthesis
|
ISO
|
GLS protein results in increased chemical synthesis of Palmitoylcarnitine
|
CTD |
PMID:31040181 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G
|
Ppp3r1
|
protein phosphatase 3, regulatory subunit B, alpha
|
decreases metabolic processing
|
ISO
|
PPP3R1 gene mutant form results in decreased metabolism of Palmitoylcarnitine
|
CTD |
PMID:19700627 |
|
NCBI chr14:91,556,743...91,606,391
Ensembl chr14:91,604,121...91,606,907
|
|
G
|
Prkaa1
|
protein kinase AMP-activated catalytic subunit alpha 1
|
increases chemical synthesis
|
ISO
|
PRKAA1 protein results in increased chemical synthesis of Palmitoylcarnitine
|
CTD |
PMID:31040181 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
|
G
|
App
|
amyloid beta precursor protein
|
increases abundance multiple interactions
|
ISO
|
APP protein mutant form results in increased abundance of propionylcarnitine PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of propionylcarnitine] [APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of propionylcarnitine
|
CTD |
PMID:39172838 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G
|
Mapt
|
microtubule-associated protein tau
|
decreases abundance multiple interactions
|
ISO
|
MAPT protein mutant form results in decreased abundance of propionylcarnitine PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of propionylcarnitine]
|
CTD |
PMID:39172838 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129
|
|
G
|
Psen1
|
presenilin 1
|
multiple interactions
|
ISO
|
[APP protein mutant form co-treated with PSEN1 protein mutant form co-treated with PF-06840003] results in decreased abundance of propionylcarnitine
|
CTD |
PMID:39172838 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|